Neurofibroma of spinal cord

Summary

Neurofibroma of spinal cord (MONDO:0001789) is a disease and 1 clinical trial. Top therapeutic interventions include cediranib maleate. A subtype of neurofibroma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).

At a glance

• Clinical trials: 1

Clinical features

No curated clinical features (Orphanet) for this disease.

Identifiers

Disease identifiers

Field	Value
Canonical name	neurofibroma of spinal cord
Mondo ID	MONDO:0001789
DOID	DOID:13742
NCIT	C5145
UMLS	C1336047
MedGen	234804
GARD	0023012
Anatomy (UBERON)	UBERON:0002240
Is cancer (heuristic)	no

Also known as: neurofibroma of spinal cord · spinal cord neurofibroma

Disease family

This is a subtype of neurofibroma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.

Classification path: disease › human disease › disease by body system or component › nervous system disorder › peripheral nervous system disorder › peripheral nervous system neoplasm › nerve sheath neoplasm › neurofibroma › neurofibroma of spinal cord

Related subtypes (10): mediastinum neurofibroma, Pacinian tumor, neurofibrosarcoma, epithelioid neurofibroma, neurofibroma of gallbladder, plexiform neurofibroma, cellular neurofibroma, atypical neurofibroma, neurofibroma of the heart, neurofibroma of the esophagus

Genetics & variants

GWAS landscape

No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.

Variant details and genetic-evidence tiers

No tiered GWAS variants or ClinVar records for this disease.

Genes & proteins

No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).

Function

No pathway enrichment — requires an associated-gene cohort.

Therapeutics

No druggable-target or therapeutic data for this disease’s cohort.

Clinical trials & evidence

Clinical trials

Clinical trials: 1.

Phase distribution (across all retrieved trials)

Phase	Trials
PHASE2	1

Top trials by phase / activity

NCT	Phase	Status	Title
NCT00326872	PHASE2	TERMINATED	AZD2171 in Treating Patients With Neurofibromatosis Type 1 and Plexiform Neurofibroma and/or Neurofibroma Near the Spine

Drugs tested across these trials (top 30)

Molecule	Max phase	Trials referencing
CEDIRANIB MALEATE	3	1